{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:59Z","timestamp":1790889959514,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The protective effect of beta-blockers, ACE inhibitors, and ARBs on anthracycline cardiotoxicity has already been demonstrated, but the effect of aldosterone antagonism, which inhibits the last step of the renin\u2013angiotensin\u2013aldosterone system (RAAS), was questioned. This study sought to investigate whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Eighty-three female patients who were diagnosed with breast cancer were included in the study. The study population was randomized into spironolactone and control groups. A dose of 25 mg\/day spironolactone was administered to the patients in the spironolactone group. There were 43 patients (mean age 50\u2009\u00b1\u200911 years) in the spironolactone group and 40 patients (mean age 51\u2009\u00b1\u200910 years) in the control group. LVEF decreased from 67.0\u2009\u00b1\u20096.1 to 65.7\u2009\u00b1\u20097.4 (P = 0.094) in the spironolactone group, and from 67.7\u2009\u00b1\u20096.3 to 53.6\u2009\u00b1\u20096.8 in the control group (P &amp;lt; 0.001). When the general linear model was applied, the interaction of LVEF decrease between groups was significantly lower in the spironolactone group than in the control group (P &amp;lt; 0.001). The diastolic functional grade of subjects in the spironolactone group was protected (P = 0.096), whereas it deteriorated in the control group (P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We showed that spironolactone administration used simultaneously with anthracycline group chemotherapeutics protects both myocardial systolic and diastolic functions. Spironolactone can be used to protect against anthracycline-induced cardiotoxicity.<\/jats:p>\n                    <jats:p>Trial registration: NCT02053974.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.196","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T02:43:31Z","timestamp":1416451411000},"page":"81-89","source":"Crossref","is-referenced-by-count":221,"title":["Protective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy"],"prefix":"10.1093","volume":"17","author":[{"given":"Mahmut","family":"Akpek","sequence":"first","affiliation":[{"name":"Erciyes University, Department of Cardiology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ozdogru","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Cardiology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Sahin","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Cardiology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mevlude","family":"Inanc","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Medical Oncology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dogan","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Cardiology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevat","family":"Yazici","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Biochemistry , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Berk","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Medical Oncology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halit","family":"Karaca","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Medical Oncology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihat","family":"Kalay","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Cardiology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Oguzhan","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Cardiology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ergin","sequence":"additional","affiliation":[{"name":"Erciyes University, Department of Cardiology , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"key":"2026011921080474600_ejhf196-bib-0001","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.1987.5.2.172","article-title":"A phase I\u2013II study of intensive-dose adriamycin for advanced breast cancer","volume":"5","author":"Jones","year":"1987","journal-title":"J Clin Oncol"},{"key":"2026011921080474600_ejhf196-bib-0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/annonc\/mdi264","article-title":"Chemotherapy dose intensity in non-Hodgkin\u2019s lymphoma: is dose intensity an emerging paradigm for better outcomes?","volume":"16","author":"Gregory","year":"2005","journal-title":"Ann Oncol"},{"key":"2026011921080474600_ejhf196-bib-0003","first-page":"355","article-title":"The impact of childhood cancer on the United States and the world","volume":"40","author":"Bleyer","year":"1990","journal-title":"CA Cancer J Clin"},{"key":"2026011921080474600_ejhf196-bib-0004","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.10833","article-title":"Childhood cancer survival in Europe and the United States","volume":"95","author":"Gatta","year":"2002","journal-title":"Cancer"},{"key":"2026011921080474600_ejhf196-bib-0005","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"2026011921080474600_ejhf196-bib-0006","first-page":"827","article-title":"Adriamycin cardiotoxicity: a survey of 1273 patients","volume":"63","author":"Praga","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"2026011921080474600_ejhf196-bib-0007","doi-asserted-by":"crossref","first-page":"646","DOI":"10.5543\/tkda.2011.01700","article-title":"Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy?","volume":"39","author":"Erdo\u011fan","year":"2011","journal-title":"Turk Kardiyol Dern Ars"},{"key":"2026011921080474600_ejhf196-bib-0008","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2003.08.008","article-title":"Aldosterone antagonism and myocardial infarction: from animals to man and back","volume":"42","author":"Solomon","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026011921080474600_ejhf196-bib-0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011921080474600_ejhf196-bib-0010","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921080474600_ejhf196-bib-0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"10","author":"Nagueh","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"2026011921080474600_ejhf196-bib-0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clon.2006.11.012","article-title":"Relationship between DNA damage and total antioxidant capacity in patients with glioblastoma multiforme","volume":"19","author":"Tuzgen","year":"2007","journal-title":"Clin Oncol"},{"key":"2026011921080474600_ejhf196-bib-0013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0735-1097(01)01309-2","article-title":"Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption","volume":"38","author":"Schimke","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026011921080474600_ejhf196-bib-0014","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","article-title":"Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"2026011921080474600_ejhf196-bib-0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/HYPERTENSIONAHA.108.121954","article-title":"Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation","volume":"53","author":"Wei","year":"2009","journal-title":"Hypertension"},{"key":"2026011921080474600_ejhf196-bib-0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats","volume":"52","author":"Michea","year":"2008","journal-title":"Hypertension"},{"key":"2026011921080474600_ejhf196-bib-0017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"2026011921080474600_ejhf196-bib-0018","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/HJH.0b013e328300a232","article-title":"Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions","volume":"26","author":"Wang","year":"2008","journal-title":"J Hypertens"},{"key":"2026011921080474600_ejhf196-bib-0019","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12185-012-1196-5","article-title":"Doxorubicin induces the DNA damage response in cultured human mesenchymal stem cells","volume":"96","author":"Cruet-Hennequart","year":"2012","journal-title":"Int J Hematol"},{"key":"2026011921080474600_ejhf196-bib-0020","first-page":"2892","article-title":"Enzymatic activation and binding of adriamycin to nuclear DNA","volume":"44","author":"Sinha","year":"1984","journal-title":"Cancer Res"},{"key":"2026011921080474600_ejhf196-bib-0021","first-page":"177","article-title":"Some observations on the toxicity of adriamycin (NSC123127)","volume":"6","author":"Philips","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"2026011921080474600_ejhf196-bib-0022","first-page":"2033","article-title":"Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit","volume":"40","author":"Breed","year":"1980","journal-title":"Cancer Res"},{"key":"2026011921080474600_ejhf196-bib-0023","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1749-6632.1982.tb31279.x","article-title":"Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity","volume":"393","author":"Legha","year":"1982","journal-title":"Ann NY Acad Sci"},{"key":"2026011921080474600_ejhf196-bib-0024","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026011921080474600_ejhf196-bib-0025","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011921080474600_ejhf196-bib-0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.phrs.2009.05.007","article-title":"Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity","volume":"60","author":"Ibrahim","year":"2009","journal-title":"Pharmacol Res"},{"key":"2026011921080474600_ejhf196-bib-0027","first-page":"382","article-title":"Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats","volume":"60","author":"Iqbal","year":"2008","journal-title":"Pharmacol Rep"},{"key":"2026011921080474600_ejhf196-bib-0028","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J Clin Oncol"},{"key":"2026011921080474600_ejhf196-bib-0029","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/1\/81\/66422994\/eurjhf_17_1_81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/1\/81\/66422994\/eurjhf_17_1_81.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:08:10Z","timestamp":1768874890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/17\/1\/81\/8426534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,11,20]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.196","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725242991.793536582","asserted-by":"object"}]},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,1]]},"published":{"date-parts":[[2014,11,20]]}}}